Home » Stocks » NRBO

NeuroBo Pharmaceuticals, Inc. (NRBO)

Stock Price: $2.97 USD 0.00 (0.00%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
After-hours: $2.99 +0.02 (0.67%) Jul 27, 7:57 PM
Market Cap 66.19M
Revenue (ttm) n/a
Net Income (ttm) -28.27M
Shares Out 22.29M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $2.97
Previous Close $2.97
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.95
Day's Range 2.83 - 3.07
Day's Volume 229,234
52-Week Range 2.70 - 7.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other stocks mentioned: NVIV, SYN
1 week ago - PennyStocks

Life Clips (LCLP) stock is falling on Tuesday following an update from the battery company about its recent business announcements. The post LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Cli...

Other stocks mentioned: IMNM
1 week ago - InvestorPlace

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...

Other stocks mentioned: IMNM, MRNA, NVAX, OCGN, QDEL
1 week ago - InvestorPlace

Neurobo Pharmaceuticals (NRBO) stock is on the rise Tuesday as retail traders take a liking to the biotechnology company. The post NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors S...

1 week ago - InvestorPlace

BOSTON, July 12, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...

2 weeks ago - PRNewsWire

BOSTON, May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies...

2 months ago - PRNewsWire

BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapi...

3 months ago - PRNewsWire

Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...

Other stocks mentioned: WINT
3 months ago - GuruFocus

BOSTON, March 24, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Continge...

4 months ago - PRNewsWire

BOSTON, Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of a...

6 months ago - PRNewsWire

BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a priva...

6 months ago - PRNewsWire

NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...

8 months ago - PRNewsWire

BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.

11 months ago - PRNewsWire

BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...

1 year ago - PRNewsWire

About NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an ac... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 16.00.

Price Target
$16.00
Analyst Consensus: Buy